Your account is not claimed yet. You can sign up with ORCID to claim your account.

Alba Ariela Brandes (Alba A Brandes, Alba Brandes)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 22

Top Venues

Expert opinion on drug discovery

Expert review of anticancer therapy

Expert review of clinical pharmacology

Immunotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Tobias Kessler, Daniel Schrimpf, Laura Doerner, Ling Hai, Leon D Kaulen, Jakob Ito, Martin J van den Bent, Martin J B Taphoorn, Alba Ariela Brandes, Ahmed Idbaïh, Julien Dômont, Paul M J Clement, Mario Campone, Martin Bendszus, Andreas von Deimling, Felix Sahm, Michael Platten, Wolfgang Wick, Antje Wick
Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert opinion on drug discovery 18 (3) (2023)
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022. Expert opinion on drug discovery (2023)
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert opinion on drug discovery 18 (3) (2023)
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert opinion on drug discovery 18 (3) (2023)
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini, Alba Ariela Brandes
Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert opinion on drug discovery (2023)
Lidia Gatto, Enrico Franceschi, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi, Alba Ariela Brandes
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert review of anticancer therapy 21 (12) (2022)
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments. Expert review of clinical pharmacology 16 (1) (2022)
Lidia Gatto, Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date? Drugs 82 (5) (2022)
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments. Expert review of clinical pharmacology 16 (1) (2022)
Martin Klein, Julie M de Kort, Alba Ariela Brandes, Walter Taal, Michael Platten, Ahmed Idbaïh, Jean Sebastien Frenel, Wolfgang Wick, Chandrakanth Jayachandran Preetha, Martin Bendszus, Philipp Vollmuth, Jaap C Reijneveld, Martin Klein
Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-oncology practice 9 (4) (2022)
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments. Expert review of clinical pharmacology (2022)
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alba Ariela Brandes
BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. Immunotherapy (2021)
Ilaria Maggio, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Vincenzo Di Nunno, Caterina Tonon, Alba Ariela Brandes
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. Expert review of anticancer therapy 21 (11) (2021)
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Caterina Tonon, Raffaele Lodi, Raffaele Agati, Stefania Bartolini, Alba Ariela Brandes
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. Clinical case reports 9 (8) (2021)
Ilaria Maggio, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Lidia Gatto, Raffaele Lodi, Alba Ariela Brandes
Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS oncology 10 (2) (2021)
Vincenzo Di Nunno, Giacomo Nuvola, Mirta Mosca, Ilaria Maggio, Lidia Gatto, Alicia Tosoni, Raffaele Lodi, Enrico Franceschi, Alba Ariela Brandes
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy 13 (5) (2021)
Enrico Franceschi, Alba Ariela Brandes
Burnout in medical oncology during the COVID-19 pandemic. Expert review of anticancer therapy 21 (4) (2020)
Alba Ariela Brandes, Andrea Ardizzoni, Fabrizio Artioli, Federico Cappuzzo, Luigi Cavanna, Giovanni Luca Frassineti, Antonio Frassoldati, Francesco Leonardi, Giuseppe Longo, Antonio Maestri, Davide Tassinari, Enrico Franceschi, Vincenzo Di Nunno, Carmine Pinto
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future oncology (London, England) 16 (20) (2020)
Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, Monica Di Battista, Lidia Gatto, Cinzia Lamperini, Santino Minichillo, Antonella Mura, Stefania Bartolini, Alba Ariela Brandes
Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert review of anticancer therapy 20 (9) (2020)
Tobias Kessler, Anne Berberich, Ahmed Sadik, Felix Sahm, Thierry Gorlia, Christoph Meisner, Dirk C Hoffmann, Antje Wick, Philipp Kickingereder, Petra Rübmann, Martin Bendszus, Christiane Opitz, Michael Weller, Martin van den Bent, Roger Stupp, Frank Winkler, Alba Ariela Brandes, Andreas von Deimling, Michael Platten, Wolfgang Wick
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer medicine 9 (22) (2020)
Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, Monica Di Battista, Giovenzio Genestreti, Santino Minichillo, Antonella Mura, Stefania Bartolini, Raffaele Agati, Alba Ariela Brandes
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? Journal of neuro-oncology 139 (2) (2018)

Alba Ariela Brandes.css-eqlu8i{font-size:small;padding-left:4px;} (Alba A Brandes, Alba Brandes)

Publication Activity (10 Years)

Top Topics

Top Venues

Alba Ariela Brandes (Alba A Brandes, Alba Brandes)